Jaemin Shin

Jaemin Shin

Auto-generated profile, based on publicly available information

Jaemin Shin

Department of Neurology, Korea University College of Medicine, Korea University Guro Hospital (J.S., K.-J.L., C.K.K., K.O.).

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 September 2022 in Korean Journal of Radiology
Verified
Journal Article
Open access
PDF file
COChuluunbaatar Otgonbaatar
Chuluunbaatar Otgonbaatar
JRJae-Kyun Ryu
Jae-Kyun Ryu
JSJaemin Shin
Jaemin Shin
JWJi Young Woo
Ji Young Woo
JSJung Wook Seo
Jung Wook Seo
DHDae Hyun Hwang
Dae Hyun Hwang
Otgonbaatar C, et al. Korean J Radiol. 2022 Sep;23:e68. https://doi.org/10.3348/kjr.2022.0127

1 March 2026 in Stroke
Verified
Journal Article
Closed access
JSJaemin Shin
Jaemin Shin
KLKeon-Joo Lee
Keon-Joo Lee
CKChi Kyung Kim
Chi Kyung Kim
KOKyumgmi Oh
Kyumgmi Oh
DKDo Yeon Kim
Do Yeon Kim
HBHee-Joon Bae
Hee-Joon Bae
BACKGROUND: Dual antiplatelet therapy (DAPT) is recommended within 24 hours for patients with minor ischemic stroke or high-risk transient ischemic attack. However, the optimal timing for initiating DAPT remains unclear. METHODS: From a prospective multicenter cohort involving 20 stroke centers between January 2011 and April 2023, patients with minor noncardioembolic ischemic stroke (National Institutes of Health Stroke Scale score ≤5) or high-risk transient ischemic attack who presented within 7 days of symptom onset were included. We evaluated outcomes based on in-hospital initiation of DAPT versus monotherapy (aspirin or clopidogrel alone). The primary outcome was a composite of recurrent stroke, myocardial infarction, and death within 90 days. Patients were grouped by time from symptom onset to hospital arrival: 0 to 24 hours, 24 to 72 hours, and >72 hours. Time-to-treatment effects were analyzed using Cox proportional hazards models, with inverse probability of treatment weighting based on propensity scores. The adjusted models incorporated demographic factors, baseline clinical characteristics, vascular risk factors, stroke subtype, relevant arterial status, and prior antiplatelet use. RESULTS: Among the 41 530 patients (mean age, 66.3 years; 25 771 [62%] male), 25 112 (60.5%) received DAPT. The 90-day primary outcome occurred in 2663 (10.7%) of the DAPT group versus 1900 (11.6%) in the monotherapy group (hazard ratio, 0.82 [95% CI, 0.77–0.87]). The benefit of DAPT was most pronounced when initiated within 24 hours (hazard ratio, 0.74 [95% CI, 0.69–0.79]). No significant benefit was observed when DAPT was initiated between 24 and 72 hours (hazard ratio, 1.00 [95% CI, 0.88–1.15]), and a higher risk was suggested for initiation beyond 72 hours (hazard ratio, 1.25 [95% CI, 1.01–1.55]). Time-dependent analysis showed a benefit crossing the null at ≈42 hours. CONCLUSIONS: Early initiation of DAPT was associated with the greatest clinical benefit, consistent with current guideline recommendations. The therapeutic effect appeared to decline progressively beyond this period, with an estimated threshold around 42 hours.